This phase II trial is evaluating Azacitidine alone and in combination with Venetoclax in patients with previously untreated Myelodysplastic Syndromes (MDS).
This trial is treating patients with Myelodysplastic Syndromes (MDS).
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.